Advances in Managing Inhibitors in Patients With Hemophilia A

Caregiver Interview Marquita Reinhardt

Patient History  

Treatment Approach

Challenges

Effect on Patient

Advances in Managing Inhibitors in Patients With Hemophilia A

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Inhibitors

Risk Factors

Management of Acute Bleeds

ITI

Predictors of ITI Success

Further Considerations for ITI

EHL Factor Products for ITI

Challenges of Managing Inhibitors

Burden of Care

Emicizumab

HAVEN 1 Results

Adverse Events

Updated Results

Clinician Experience

Changes to Practice

Novel Approaches Overcoming Inhibitors

Fitusiran

Further "Off-Switch" Approaches

ITI in the Context of Emicizumab and Novel Therapies

Concluding Remarks

Abbreviations

Abbreviations (cont)